Incretin-Based Drugs: Markets for Diabetes Therapies and Developing Treatments

Feb 2015| PHM162A| BCC Publishing

Report Highlights

The global market for incretin-based therapeutics was valued at nearly $11.8 billion in 2013 and $12.7 billion in 2014. This market is expected to reach $22.8 billion by 2019, with a compound annual growth rate (CAGR) of 12.4% from 2014 to 2019.

Report Includes

  • An overview of the global diabetes treatment market.
  • Analyses of global market trends, with data from 2012 to 2014, and projections of CAGRs through 2019.
  • Information on the field of glucagon-like peptide-1 (GLP-1) receptor agonists and dipeptidyl peptidase-4 (DPP-4) inhibitors collectively known as incretin-based therapies, a drug category used mainly for the control of diabetes but that also have potential indications for cardiovascular treatment and even weight loss.
  • Drug sales earned according to therapeutic area as well as by geography.
  • Analysis of the market's dynamics, specifically major issues, and challenges.
  • Relevant intellectual property (IP) and patent analysis.


The scope of this study encompasses companies that are involved in diabetes prevention as well as detection, diagnosis and treatment. BCC Research analyzes each technology or therapy type, determines its current market status, examines its impact on future markets and presents forecasts of growth over the next five years. Technological issues, including the latest trends, are discussed.

Analyst Credentials

Kim Lawson is a graduate of Mount Holyoke College with a degree in English Literature and an M.A. in management from Harvard University's extension program. She acquired experience as a healthcare journalist, including working for John Wiley & Sons as a print reporter, before serving as a research analyst in a small market research firm (in the Research Triangle Park area of North Carolina) that focused on pharmaceuticals and biotechnology. Before joining that firm, she published two reports on emerging and established diagnostics and therapeutics for benign and cancerous breast disease.

Table of Contents & Pricing

All reports provided in PDF format. For shared licensing options (5+ Users), please call a representative at (+1) 781-489-7301 or contact us at
Title/Chapter NamePagesPrice Member Price
Full Report: Incretin-Based Drugs: Markets for Diabetes Therapies and Developing Treatments136 $2,750 Free
Chapter- 1: INTRODUCTION3Free
Chapter- 2: EXECUTIVE SUMMARY8$250Free
Chapter- 5: COMPANY PROFILES47$950Free
Incretin-Based Drugs: Markets for Diabetes Therapies and Developing Treatments

Single User License: $2750

Member Price: FREE

Have a Question? Ask Us.

Why BCC Research.?

Every purchase provides access to:

  • Thousands of recently published reports from select publishers
  • Member Discounts of up to 50% on over 20,000 additional reports from all publishers
  • Our analysts and research concierge for all inquiries